Two Extended-Release Morphine Sulfate Formulations for Cancer Pain

  1. a patient preference study comparing two extended-release morphine sulfate formulations for cancer pain



    from clinical drug investigation [tm]
    posted 01/01/2000


    robert o. kerr, southwest regional cancer center, austin, texas, usa; william j. tester, albert einstein cancer center, philadelphia, pennsylvania, usa



    abstract and introduction

    abstract

    objective: to compare pain control, patient preference and tolerability for two extended-release formulations of morphine sulfate, kadian® capsules (administered once daily) and ms contin® tablets (administered twice daily), in the treatment of chronic cancer pain.
    patients and methods: a randomised, open-label, multicentre, crossover study was conducted in 178 patients requiring treatment for cancer pain, of which 134 were included in the tolerability analysis and 114 took part in the efficacy analysis. primary efficacy measures yielded pain scores, which were analysed with repeated measures analysis of variance (anova), and patient preference was analysed with a goodness-of-fit chi2 test. secondary efficacy measurements and tolerability assessments were analysed using an anova model.
    results: a total of 57 of 104 patients (55%) preferred treatment with kadian®, 34 (33%) preferred treatment with ms contin®, and 13 (12%) had no preference (p = 0.001). there were no clinically important, statistically significant differences between kadian® and ms contin® in pain assessments, rescue medication usage, investigator global assessments, health-related quality-of-life measures, morphine-related adverse effects, other adverse events, or dropout rates.
    conclusion: patient preference for kadian® over ms contin® may reflect benefits of once-daily versus twice-daily administration, since both treatments provided comparable pain control and tolerability profiles.

    http://www.medscape.com/viewarticle/406155
    •  
  2. 3 Comments

  3. by   aimeee
    Off the subject, but why don't we see the same problems with abuse of MS-Contin and Kadian that we do with Oxycontin?
  4. by   kids
    Quote from aimeee
    Off the subject, but why don't we see the same problems with abuse of MS-Contin and Kadian that we do with Oxycontin?
    Good question Amy. My guess (based on personal experience) is cost.

    My Kadian costs the insurance company (you may want to sit down for this)...$580/mo. I had to "fail" on MS Contin...twice, to get Kadian covered.
    My mom's MS Contin cost about $240/mo. Her ONC switched her to Oxycontin for several reasons and it cost $140/mo (thank God, she had no medication coverage).
  5. by   aimeee
    Gee, that surprises me. I still have a copy of a slide from a presentation I went to by a Pharm D that showed opioid cost comparison. The data is taken from the average wholesale price in 2001 and shows a monthly cost of $569.59 for 90 mg. of continous release oxycodone versus $305.00 for continuous release morphine.

close